NCT00524667 - HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Valproic acid & fludarabine

valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until \>1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.

Trial Locations (1)

R3E 0V9

CancerCare Manitoba, Winnipeg